Identifying the Hr-HPV infections that really matter
Our E6/E7 mRNA technology focuses on the prevention and early detection of all HPV-related cancers
7 HPV-genotypes account for about 80% to 90% of cervical cancers
Preserving life through prevention and early detection
PRETECT HPV E6/E7 mRNA
Improved protection against cervical cancer
Human papillomaviruses (HPV) have been identified as the cause of almost all cervical cancers. 14-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) have been identified as high-risk (Hr-HPV) for cervix cancer, but even among them, risk varies. Two genotypes, HPV 16 and HPV 18, cause about 60-75% of cervical cancer, and HPV 31, 33, 45, 52, and 58 causes about 20%.
Knowledge of the HPV mRNA genotype status dramatically assists in the clinical decision-making of a patient’s risk of having disease now or shortly after, and in choosing the next appropriate management step.
We offer clinical service testing at our ISO 13485:2016 certified laboratory.
The urgent need to more accurately identify the women who are warranted for colposcopy is highly addressed by clinicians to reduce unnecessary interventions.
OUR PRODUCTS
In vitro molecular reagents
Molecular reagents: Our proprietary RNA-guided molecular genetic technology makes use of multifunctional molecular biomarkers
Sample Preparation solutions: High-performance laboratory sample prep reagents are compatible with our flagship products as well as other brands
IN-VITRO mRNA TECHNOLOGY
WHY HPV E6/E7 mRNA IN TRIAGE FOR HPV POSITIVES
TESTIMONIALS
TESTIMONIALS
